[Epidemiology and therapy of Campylobacter pylori infection].
The prevalence of Campylobacter pylori in gastric mucosa was investigated prospectively (by histology, cytology, bacterial culture and urease rapid-test) in 302 patients of a routine gastroenterological endoscopy programme. According to the histopathological findings the following prevalence of C. pylori was established: 3 of 35 normals (9%); 116 of 167 with antral gastritis (69%), 28 of 40 with gastric ulcers (70%); 26 of 33 with duodenal ulcers (79%); 5 of 27 with other conditions (19%). The activity degree of the gastritis correlated closely with the presence of C. pylori. In a prospective open trial 110 patients with antral gastritis or gastroduodenal ulcer were treated according to the following schedule: (a) bismuth subsalicylate, 1800 mg/d for four weeks (35 patients); (b) amoxycillin 2250 mg/d for two weeks (6); (c) ranitidine 300 mg/d for four weeks (26); (d) bismuth plus amoxycillin (20); (e) bismuth plus ranitidine (23). Immediately after the end of treatment and four weeks later the elimination rates were: (a) bismuth 51% (18) and 23% (8), respectively; (b) amoxycillin 50% (3) and 17% (1); (c) ranitidine 0% (0); (d) bismuth plus amoxycillin 60% (12) and 25% (5); (e) bismuth plus ranitidine 43% (10) and 17% (4). These data indicate that treatment with bismuth plus amoxycillin will achieve a negative bacterial result in about half the patients. But frequently as early as four weeks later C. pylori can again be demonstrated, so that the long-term elimination rate is only 15-30%.
Wagner
S
S
Abteilung für Gastroenterologie und Hepatologie im Zentrum Innere Medizin, Medizinische Hochschule Hannover.
Freise
J
J
Bär
W
W
Fritsch
S
S
Schmidt
F W
FW
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000658:Amoxicillin / Q000627:therapeutic use; D001706:Biopsy; D001729:Bismuth; D002167:Campylobacter / Q000302:isolation & purification; D002169:Campylobacter Infections / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004386:Duodenum / Q000382:microbiology / Q000473:pathology; D005260:Female; D005767:Gastrointestinal Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D005773:Gastroscopy; D005860:Germany, West; D006801:Humans; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000627:therapeutic use; D011446:Prospective Studies; D011899:Ranitidine / Q000627:therapeutic use; D012459:Salicylates / Q000627:therapeutic use; D013270:Stomach / Q000382:microbiology / Q000473:pathology
D009942:Organometallic Compounds; D012459:Salicylates; C015715:bismuth subsalicylate; D000658:Amoxicillin; D011899:Ranitidine; D001729:Bismuth
Epidemiologie und Therapie der Campylobacter-pylori-Infektion.